14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
BUDA vs EXOZ: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, BUDA (BUDA) captures the overall head-to-head institutional edge over eXoZymes Inc. (EXOZ) on higher Unified Composite conviction (34.2/100 SELL vs. 42.3/100 HOLD) after splitting the core matrix 1–6 (led by Options & Positioning), while EXOZ wins 3–1 across the 6-pillar growth and valuation breakdown. BUDA trades at $5.30 (N/M Forward P/E, N/A operating margin) versus EXOZ at $2.90 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While EXOZ currently prints a higher short-term Unified Composite Score (42.3/100 HOLD vs. BUDA 34.2/100 SELL), BUDA captures the overall institutional head-to-head verdict (1–6 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (N/A vs. 0.0% operating margin) and revenue trajectory (N/A vs. +0.0% YoY).
Technical & Structure Timing Caution: BUDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.2); meanwhile EXOZ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BUDA vs EXOZ. Trailing 12-month operating profitability (BUDA N/A vs EXOZ 0.0%) and valuation multiples (BUDA N/M vs EXOZ N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $31.9M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ BUDA vs EXOZ Key Questions & Quantitative Answers
As of Nov 20, 2026, BUDA (BUDA) captures the overall head-to-head institutional edge over eXoZymes Inc. (EXOZ) on higher Unified Composite conviction (34.2/100 SELL vs. 42.3/100 HOLD) after splitting the core matrix 1–6 (led by Options & Positioning), while EXOZ wins 3–1 across the 6-pillar growth and valuation breakdown. BUDA trades at $5.30 (N/M Forward P/E, N/A operating margin) versus EXOZ at $2.90 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While EXOZ currently prints a higher short-term Unified Composite Score (42.3/100 HOLD vs. BUDA 34.2/100 SELL), BUDA captures the overall institutional head-to-head verdict (1–6 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (N/A vs. 0.0% operating margin) and revenue trajectory (N/A vs. +0.0% YoY). Technical & Structure Timing Caution: BUDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.2); meanwhile EXOZ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
EXOZ leads the Growth & Scale pillar: BUDA posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with EXOZ at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, BUDA generates N/A in USD-normalized revenue versus N/A for EXOZ. In operating R&D and SG&A reinvestment, BUDA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EXOZ.
BUDA and EXOZ trade at balanced relative valuation multiples. BUDA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas EXOZ trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BUDA (N/A ROE) versus EXOZ (-187.2% ROE) capital efficiency.
In options market volatility and institutional positioning, BUDA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.03β · 71% Vol realized risk). By comparison, EXOZ carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.86β · 109% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.